eflornithine has been researched along with Cancer of Duodenum in 2 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, CA | 1 |
| Dekker, E | 1 |
| Samadder, NJ | 1 |
| Stoffel, E | 1 |
| Cohen, A | 1 |
| Lehnert, T | 1 |
| Buhl, K | 1 |
| Ivankovic, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis[NCT01483144] | Phase 3 | 171 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Improved | Not Improved | |
| Eflornithine Plus Sulindac | 22 | 34 |
| Eflornithine Plus Sulindac Placebo | 16 | 41 |
| Sulindac Plus Eflornithine Placebo | 22 | 36 |
Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Improved | Not Improved | |
| Eflornithine Plus Sulindac | 11 | 45 |
| Eflornithine Plus Sulindac Placebo | 10 | 47 |
| Sulindac Plus Eflornithine Placebo | 10 | 48 |
Progression of disease by evaluation of FAP-related events over the course of study treatment (NCT01483144)
Timeframe: Up to 48 months from the start of treatment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number with FAP-related events | Number with Lower GI FAP-related events | |
| Eflornithine Plus Sulindac | 18 | 2 |
| Eflornithine Plus Sulindac Placebo | 23 | 10 |
| Sulindac Plus Eflornithine Placebo | 22 | 9 |
1 trial available for eflornithine and Cancer of Duodenum
| Article | Year |
|---|---|
Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2016 |
1 other study available for eflornithine and Cancer of Duodenum
| Article | Year |
|---|---|
Inhibition of gastric tumorigenesis by alpha-difluoromethylornithine in rats treated with N-methyl-N'-nitro-N-nitrosoguanidine.
Topics: Adenocarcinoma; Adenoma; Animals; Cell Transformation, Neoplastic; Duodenal Neoplasms; Eflornithine; | 1993 |